AI-Powered Cellular Reprogramming Attracts Major Investment as Biotech Firms Target US$610 Billion Longevity Market
核心洞察
A six-year-old biotech start-up raised US$269.5 million in its Hong Kong IPO on May 13, with cornerstone investments from BlackRock (搜索) and UBS Asset Management Singapore (搜索) totaling US$148 million.
The company uses AI algorithms to design nano-delivery platforms that deliver drug payloads into specific cells and organs, aiming to reprogram cellular errors associated with ageing.
The United States currently leads the global cellular reprogramming field, accounting for 57% of all longevity companies and 84% of total deal volume, according to a 2024 Longevity Technology report.
A biotechnology start-up leveraging artificial intelligence to combat cellular ageing has raised US$269.5 million through its initial public offering on the Hong Kong Stock Exchange on May 13, marking one of the most significant capital raises in the emerging longevity biotechnology sector. Cornerstone investors BlackRock (搜索) and UBS Asset Management Singapore (搜索) subscribed a combined US$148 million, signaling strong institutional confidence in the company's AI-driven approach to cellular reprogramming.
The six-year-old firm is developing AI algorithms to design nano-delivery platforms capable of transporting drug payloads into specific cells and organs, a technological foundation that underpins its strategy to address age-related cellular decline.
Reprogramming the Biology of Ageing
The company's scientific rationale centers on the concept that cellular errors accumulate over time and that these errors can be corrected through reprogramming. "Those errors can be reprogrammed. It becomes possible to use AI to read, rewrite and reverse cells, or at least slow the ageing process," said Lai, a representative of the company, in an interview with the South China Morning Post.
Lai elaborated on the therapeutic strategy, noting that the process could begin by targeting immune cells whose function deteriorates with age. "Immune cells, such as T cells, as their function declines after old age. That is why older people become more susceptible to cancer (搜索) and all kinds of disease," he added. This focus on T-cell rejuvenation highlights a specific immunological entry point for the company's broader anti-ageing ambitions.
A Rapidly Expanding Global Market
The longevity biotechnology field, while still in early stages of development, has seen rapid advances driven by substantial private investment. The United States currently dominates the global landscape, accounting for 57% of all longevity companies worldwide and 84% of total deal volume, according to a 2024 report published by Longevity Technology. Global investment in the sector has reached US$8.49 billion, underscoring the scale of financial commitment to technologies aimed at extending healthspan and potentially reversing aspects of biological ageing.
The US leadership position has been fueled by "massive, multibillion-dollar private investments and research and development," positioning cellular reprogramming as a cornerstone technology in the race to address age-related diseases at their molecular roots.
Nano-Delivery and AI Convergence
The convergence of artificial intelligence with nano-delivery platforms represents a key technological differentiator in the company's approach. By using AI to design delivery systems that can precisely target specific cells and organs, the firm aims to overcome one of the central challenges in cellular reprogramming: achieving therapeutic effects in the right tissues without off-target consequences. This precision medicine approach aligns with broader industry trends toward targeted biological interventions for complex, multifactorial conditions associated with ageing.